Novartis International AG is a multinational pharmaceutical company based in Basel, Switzerland, ranking number three in sales among the world-wide industry.[when?] Company sales totalled 36.173 billon US$ in 2008. Currently,[when?] Novartis is the sixth largest pharmaceutical company in terms of revenue ($41.5 billion in 2009) with a profit margin of about 20%, which is the same as its industry competitors. Novartis profits were down by 31% from 2007 levels. Novartis manufactures such drugs as clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate and (Gleevec / Glivec). Additional agents include ciclosporin (Neoral / Sandimmun), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil), and others. Renamed to Novartis following an acquisition by Ciba-Geigy, it owns Sandoz, a large manufacturer of generic drugs. The company formerly owned the Gerber Products Company, a major infant and baby products producer, but sold it to Nestlé on 1 September 2007.
Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:
- contributions under $200 are not reported, and so are not included in totals.
- only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
- contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
- corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
- organization totals include known subsidiaries of the organization.
Latest FEC Datacovers through committee's December 31, 2010 filing.
Summaryoverview of the committee's finances
- Total Raised:
- Total Spent:
- Cash on Hand:
Standardized Donation Informationcovers roughly through Q4 2012. may lag behind FEC section above, as donors and industries are identified by hand.
- Employee Color Block
- PAC Color Block
Republicans vs. Democratsin dollars. "Other" includes 3rd parties and organizations without official party affiliation.
State vs. Federalin dollars
Top PAC Recipients
- Employee Color Block
- PAC Color Block
Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying on Behalf of Novartis AG
Names of Lobbyists
Firm Hired Amount Novartis Corp $12,643,670 Ruder Finn Inc $0
Most Frequently Disclosed Lobbying Issues
- Health Issues,
- Fed Budget & Appropriations,
- Medicare & Medicaid,
- Copyright, Patent & Trademark,
- Government Issues,
Most Frequently Disclosed Bills
Bill No. Title H.R.3590 Service Members Home Ownership Tax Act of 2009 H.R.3200 America's Affordable Health Choices Act of 2009 H.R.1548 Pathway for Biosimilars Act H.R.1427 Promoting Innovation and Access to Life-Saving Medicine Act H.R.1 American Recovery and Reinvestment Act of 2009 S.301 Physician Payments Sunshine Act of 2009 H.R.4213 Tax Extenders Act of 2009 H.R.4899 Disaster Relief and Summer Jobs Act of 2010 H.R.3962 Affordable Health Care for America Act S.726 Promoting Innovation and Access to Life-Saving Medicine Act
RegulationsMentioned in 95 dockets; Submitted to 8 dockets
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "Novartis AG" in public comments on proposed federal regulations.
Documents Submitted by the Organization
View all submissions data for Novartis AG
- Toggle 3 FDA Draft Guidance for Industry on Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications; Availability 2009
- Toggle 2 FDA Risk Evaluation and Mitigation Strategies; Notice of Public Meeting; Reopening of Comment Period 2010
- Toggle 1 FDA Promotion of FDA-Regulated Medical Products Using the Internet and Social Media Tools; Notice of Public Hearing 2009
- Toggle 1 FDA Petiton Regarding Appropriate Role in the Development and Implementation of REMS Program 2010
- Toggle 1 FDA Converged Communications and Health Care Devices Impact on Regulation; Public Meeting; Request for Comments 2010
- Toggle 1 FDA Draft Guidance for Industry on CMC Postapproval Manufacturing Changes Reportable in Annual Reports; Availability 2010
- Toggle 1 FDA FDA Transparency Task Force; Public Meeting 2009
- Toggle 1 NIH Public Meeting on Expansion of the Clinical Trial Registry and Results Data Bank 2009
Mentions in Document Text
View all mentions data for Novartis AG
- Toggle 9 FDA Patent Term Extension Application for AFINITOR® (everolimus), U.S. Patent No. 5,665,772 CLOSED 2009
- Toggle 7 PHMSA Hazardous Materials: Harmonization with International Standards 2009
- Toggle 6 FDA Patent Term Extension Application for BANZEL™ (rufinamide), US Patent No. 6,740,669 - CLOSED 2009
- Toggle 6 FDA Patent Term Extension Application for Coartem™ (artemether/lumefantrine), U.S. Patent No. 5,677,331 2009
- Toggle 5 FDA Request FDA Determine That the Proposed Imatinib Mesylate Capsules Drug Products in Strengths of 200 mg, 400 mg, and 600 mg are Suitable for Submission in an Abbreviated New Drug Application ("ANDA") 2010
- Toggle 4 FDA Advisory Committee, Workshops, and Conferences Notices Various Meetings Notices (eg., Task Force Meeting, etc.) 2010
- Toggle 4 FDA Patent Term Extension Application for Ilaris® (canakinumab), US. Patent No. 7,446,175 2010
- Toggle 3 FDA Advisory Committee, Workshops, and Conferences Notices Various Meetings Notices (eg., Task Force Meeting, etc.) 2009
- Toggle 3 FDA Novartis Pharmaceuticals Corp. et al.; Withdrawal of Approval of 27 New Drug Applications and 58 Abbreviated New Drug Applications. 2010
- Toggle 3 PHMSA Hazardous Materials Revision to Requirements for the Transportation Lithium Batteries 2009
Contractor Misconduct7 Instances
This information is collected by the Project On Government Oversight from press releases, court documents, news reports and other public records. It is not meant to be an exhaustive account of all instances of federal contractor misconduct.
More information on each instance, including primary source documents, is available on POGO's site by clicking on the instance description. More information on POGO's methodology is available here.
|Misconduct Type||Hired By||Incident||Year||Disposition||Penalty|
|Government Contract Fraud||Health and Human Servs.||Off-Label Promotion of Trileptal (Civil Litigation)||2010||Settlement||$237,500,000|
|Health||None||Off-Label Promotion of Trileptal (Criminal Prosecution)||2010||Pleaded Guilty||$185,000,000|
|Government Contract Fraud||Multiple Agencies||False Claims Involving TOBI Cystic Fibrosis Drug||2010||Settlement||$72,500,000|
|Antitrust||None||Hawaii Average Wholesale Price Litigation||2010||Settlement||$10,000,000|
|Government Contract Fraud||Health and Human Servs.||Conrad v. Eon Labs (False Claims)||2010||Settlement||$3,500,000|
|Labor||None||Breeden v. Novartis (FMLA Retaliation)||2010||Judgment Against Defendant||$579,338|
|Health||None||FDA Review of Gleevec Promotional Material||2010||Investigative Finding||$0|
EPA Violations1 Enforcement Actions
Figures are based on data from the Environmental Protection Agency’s ECHO website. The ECHO database contains federal and state environmental enforcement actions. Data displayed here includes only those actions that began after 2000 and resulted in fines of over $1 million.
Actions where the company was the sole defendant are listed first. Actions where the company is one of multiple defendants are listed subsequently.
For more information see our EPA methodology page.
|Old Southington Landfill||Ciba Corporation & Novartis Corporation (+85 others)||2009||Southington, Ct||$4,248,450|
Advisory Committees1 person on 1 committee
Data is based on disclosures required by the Federal Advisory Committee Act (FACA). Matches are based on the occurrence of the company name in the committee member affiliation. Variations in company names may cause some matches to be missed.
The table shows only the top 10 agencies. To search and download raw records from the complete dataset see the FACA data section.